Cancer Treatment Reviews
Volume 37, Issue 2 , Pages 127-132 , April 2011

Advances in the systemic treatment of pancreatic neuroendocrine tumors

  • Suayib Yalcin

      Affiliations

    • Corresponding Author InformationTel.: +90 (312) 3052910; fax: +90 (312) 3092912.

Received 5 May 2010 ,Revised 6 July 2010 ,Accepted 11 July 2010.

References 

  1. Yalcin S, Oyan B, Bayraktar Y. Current medical treatment of pancreatic neuroendocrine tumors. Hepatogastroenterology. 2007;54:278–284
  2. Ehehalt F, Saeger HD, Schmidt CM, Grutzman R. Neuroendocrine tumors of the pancreas. Oncologist. 2009;14:454–467
  3. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol. 2008;26:3063–3072
  4. Vortmeyer AO, Huang S, Lubensky I, Zhuang Z. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab. 2004;89:1934–1938
  5. Burnik FS, Yalcin S. NF-kappa gene polymorphism in NET. Chemotherapy 2009. Chemotherapy. 2009;55:381–385
  6. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12:1083–1092
  7. Zikusoka MN, Kidd M, Eick G, et al. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer. 2005;104:2292–2309
  8. Halfdanarson TR, Rabe KG, Rubin J, et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–1733
  9. Moldow RE, Connelly RR. Epidemiology of pancreatic cancer in Connecticut. Gastroenterology. 1968;55:677–686
  10. Hill JS, McPhee JT, McDade TP, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009;115:741–751
  11. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753–781
  12. Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007;14:3492–3500
  13. Fesinmeyer MD, Austin MA, Li CI, et al. Differences in survival by histological type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1766–1773
  14. Bilimoria KY, Bentrem DJ, Merkow RP, et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg. 2007;205:558–563
  15. Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res. 2004;120:139–161
  16. Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci. 1991;36:933–942
  17. Zikusoka MN, Kidd M, Eick G, et al. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer. 2005;104:2292–2309
  18. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci. 2004;1014:13–27
  19. Solcia E, Klöppel G, Sobin LH. Histological typing of endocrine tumours. In: World Health Organization International Classification of Tumours. Berlin: Springer; 2000. p. 61–8.
  20. Rindi G, Klöppel G, Ahlman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401
  21. Sobin LH, Gospodarowicz MK, Wittekind C. UICC: TNM classification of malignant tumours. 7th ed.. Oxford: Wiley-Blackwell; 2009;
  22. Capdevila J, Salazar R. Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors. Targ Oncol. 2009;4:287–296
  23. Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol. 1999;10(Suppl. 2):S31–S38
  24. Shah T, Caplin M. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol. 2005;19:617–636
  25. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996;38:430–438
  26. Saltz L, Trochanowski B, Buckley M, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993;72:244–248
  27. Arnold R, Muller H, Schade-Brittinger C, et al. Placebo-controlled, double blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009;27:15s [Suppl., abstr. 4508].
  28. Oberg K, Eriksson B. The role of interferons in the management of carcinoid tumours. Br J Haematol. 1991;79(Suppl. 1):74–77
  29. Pavel ME, Baum U, Hahn EG, et al. Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res. 2006;26:8–13
  30. Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the international lanreotide and interferon alfa study group. J Clin Oncol. 2003;21:2689–2696
  31. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozotocin-doxorubicin, streptozotocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. N Engl J Med. 1992;326:519–523
  32. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med. 1994;120:302–309
  33. Ramanathan RK, Cnaan A, Hahn RG, et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern cooperative oncology group-E6282. Ann Oncol. 2001;12:1139–1143
  34. Sun W, Lipsitz S, Catalano P, et al. Eastern cooperative oncology group: Phase II/III study of doxorubicin with fluorouracil compared with streptozotocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern cooperative oncology group study E1281. J Clin Oncol. 2005;23:4897–4904
  35. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13:2896–2991
  36. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009;15:338–345
  37. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastaticneu roendocrine tumors. J Clin Oncol. 2006;24:401–406
  38. Isacoff WH, Moss RA, Pecora AL, Fine RL. Temozolomide/capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review. J Clin Oncol 2006;24(18S). ASCO annual meeting proceedings, part I [June 20 Suppl.].
  39. Fine RL, Fogelman DR, Schreibman SM. Effective treatment of neuroendocrine tumors with temozolomide and capecitabine. J Clin Oncol 2005;23(16S). ASCO annual meeting proceedings, part I of II. p. 4216 [June 1 Suppl.].
  40. Kulke MH, Stuart K, Earle CC. Aphase II studyof temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24(18S). ASCO annual meeting proceedings, part I [June 20 Suppl.].
  41. Kulke MH, Lens H, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403–3410
  42. Raymond E, Niccoli-Sire P, Bang Y, et al. Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET). In: 2010 gastrointestinal cancers symposium abstract no. 127.
  43. Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2010;28:245–255
  44. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Brit J Cancer. 2006;95:1148–1154
  45. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26:4311–4318
  46. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28:69–76
  47. Yao JC, Shah M, Ito T et al. Everolimus versus placebo in patients with advanced pancreatic neuroendocrine tumors (pNET) (RADIANT-3). In: Presented at 12 world congress on gastrointestinal cancer, Barcelona, Spain, 30 June–3 July, 2010.
  48. Phan AT, Yao JC, Fogelman DR, et al. A prospective multiinstitutional phase II study of GW786034(pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). ASCO 2010 abstr. 4001.
  49. Hobday T, Rubin J, Holen K, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. In: ASCO annual meeting, abstract # 4504, 2007.
  50. Pavel M, Bartel C, Heuck F, et al. Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC). J Clin Oncol 2008;26 [Suppl., abstr. 14684].
  51. Anthony L, Chester M, Michael S, et al. Phase II open-label clinical trial of vatalanib (PTK/ZK) in patients with progressive neuroendocrine cancer. J Clin Oncol 2008;26 [Suppl., abstr. 14624].
  52. Hobday T, Holen K, Donehower R, et al. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol 2006;24(18S). ASCO annual meeting proceedings part I. p. 4043 [June 20 Suppl.].
  53. Gross DJ, Munter G, Bitan M, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocrine-related Cancer. 2006;13:535–540
  54. Rothenberg M, Tolcher A, Sarantopoulos J, et al. AMG 479 monotherapy to treat patients with advanced GI carcinoid tumors: a subset analysis from the first-in-human study. In: Gastrointestinal cancers symposium, abs. #3862009.
  55. Di Cosimo S, Seoane J, Guzman M et al. Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the ınsulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: a mechanistic based anti-tumor strategy. Proc Am Soc Clin Oncol 2005;23(16S):3112.
  56. Gaur P, Samuel S, Bose D et al. Blockade of in vivo tumor growth of newly established human midgut carcinoid tumors by Src inhibition. In: ASCO gastrointestinal cancers symposium, 2009, 146.
  57. Shah M, Martin E, Ellison C, et al. A phase II study of proteasome inhibitor PS-341 in metastatic neuroendocrine tumors. Proc Am Soc Clin Oncol 2002;21 [abstr. 111] .
  58. Sung M, Kvols L, Wolin E, et al. Phase II proof-of-concept study of atiprimod in patients with advanced low- to intermediate-grade neuroendocrine carcinoma. J Clin Oncol 2008:26 [Suppl., abstr. 4611] .
  59. Lubner S, Chen H, Holen K, et al. A phase II clinical and biological study of lithium carbonate (Li) in patients with low-grade neuroendocrine tumors. J Clin Oncol 2009;27 [Suppl., abstr. e15662].

PII: S0305-7372(10)00128-3

doi: 10.1016/j.ctrv.2010.07.003

Cancer Treatment Reviews
Volume 37, Issue 2 , Pages 127-132 , April 2011

Article Tools